JP3362313B2 - Sake production method and the resulting sake - Google Patents
Sake production method and the resulting sakeInfo
- Publication number
- JP3362313B2 JP3362313B2 JP2000105456A JP2000105456A JP3362313B2 JP 3362313 B2 JP3362313 B2 JP 3362313B2 JP 2000105456 A JP2000105456 A JP 2000105456A JP 2000105456 A JP2000105456 A JP 2000105456A JP 3362313 B2 JP3362313 B2 JP 3362313B2
- Authority
- JP
- Japan
- Prior art keywords
- sake
- fermentation
- basidiomycete
- activity
- alcohol dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 42
- 241000221198 Basidiomycota Species 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 57
- 238000000855 fermentation Methods 0.000 claims description 51
- 230000004151 fermentation Effects 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 28
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 28
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 26
- 239000004382 Amylase Substances 0.000 claims description 20
- 102000013142 Amylases Human genes 0.000 claims description 20
- 108010065511 Amylases Proteins 0.000 claims description 20
- 235000019418 amylase Nutrition 0.000 claims description 20
- 229920002472 Starch Polymers 0.000 claims description 19
- 239000008107 starch Substances 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 9
- 241000121220 Tricholoma matsutake Species 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 235000010099 Fagus sylvatica Nutrition 0.000 claims description 5
- 240000000731 Fagus sylvatica Species 0.000 claims description 5
- 240000008397 Ganoderma lucidum Species 0.000 claims description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 4
- 240000001080 Grifola frondosa Species 0.000 claims description 4
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 4
- 235000002469 Clitocybe nuda Nutrition 0.000 claims description 3
- 241001489124 Boletus edulis Species 0.000 claims description 2
- 244000299480 Clitocybe nuda Species 0.000 claims description 2
- 240000002769 Morchella esculenta Species 0.000 claims description 2
- 235000002779 Morchella esculenta Nutrition 0.000 claims description 2
- 241000124033 Salix Species 0.000 claims description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 3
- 235000017491 Bambusa tulda Nutrition 0.000 claims 3
- 241001330002 Bambuseae Species 0.000 claims 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 3
- 239000011425 bamboo Substances 0.000 claims 3
- 241001070941 Castanea Species 0.000 claims 1
- 235000014036 Castanea Nutrition 0.000 claims 1
- 244000205754 Colocasia esculenta Species 0.000 claims 1
- 235000006481 Colocasia esculenta Nutrition 0.000 claims 1
- 240000006499 Flammulina velutipes Species 0.000 claims 1
- 235000016640 Flammulina velutipes Nutrition 0.000 claims 1
- 241000255777 Lepidoptera Species 0.000 claims 1
- 244000007853 Sarothamnus scoparius Species 0.000 claims 1
- 241000242583 Scyphozoa Species 0.000 claims 1
- 244000092524 Sinocalamus latiflorus Species 0.000 claims 1
- 235000015874 Sinocalamus latiflorus Nutrition 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 235000019992 sake Nutrition 0.000 description 88
- 239000000243 solution Substances 0.000 description 28
- 240000007594 Oryza sativa Species 0.000 description 19
- 235000007164 Oryza sativa Nutrition 0.000 description 19
- 235000009566 rice Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 11
- 229920002498 Beta-glucan Polymers 0.000 description 10
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 9
- 240000006439 Aspergillus oryzae Species 0.000 description 8
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000004019 antithrombin Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 241000222518 Agaricus Species 0.000 description 3
- 244000251953 Agaricus brunnescens Species 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 229920002488 Hemicellulose Polymers 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241001327634 Agaricus blazei Species 0.000 description 2
- 244000028550 Auricularia auricula Species 0.000 description 2
- 235000000023 Auricularia auricula Nutrition 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241000222689 Laetiporus Species 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 244000103635 Lyophyllum ulmarium Species 0.000 description 2
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 description 2
- 241000722337 Pholiota Species 0.000 description 2
- 241000743698 Pinicola Species 0.000 description 2
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 2
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 2
- 241000221987 Russula Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 241000222485 Agaricales Species 0.000 description 1
- 241000222509 Agaricus edulis Species 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000959626 Calvatia Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000222356 Coriolus Species 0.000 description 1
- 108010025600 DNA polymerase iota Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 241001149422 Ganoderma applanatum Species 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 241000123222 Hericium Species 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001534813 Hypsizygus Species 0.000 description 1
- 241001534815 Hypsizygus marmoreus Species 0.000 description 1
- 241001600027 Leccinum Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 244000290281 Lepista nuda Species 0.000 description 1
- 240000005856 Lyophyllum decastes Species 0.000 description 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 1
- 241000221638 Morchella Species 0.000 description 1
- 244000232885 Naematoloma sublateritium Species 0.000 description 1
- 235000016009 Naematoloma sublateritium Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 241000998584 Nuda Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 244000168667 Pholiota nameko Species 0.000 description 1
- 235000014528 Pholiota nameko Nutrition 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000176385 Ramaria botrytis Species 0.000 description 1
- 241000222557 Rhizopogon Species 0.000 description 1
- 241000292488 Rhizopogon roseolus Species 0.000 description 1
- 241000003632 Rhizopogon rubescens Species 0.000 description 1
- 241000380060 Riolus Species 0.000 description 1
- 241000162695 Russula delica Species 0.000 description 1
- 241000190070 Sarracenia purpurea Species 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 241000121219 Tricholoma Species 0.000 description 1
- 241000498996 Tricholoma robustum Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102200129509 rs186996510 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Landscapes
- Alcoholic Beverages (AREA)
Description
【0001】[0001]
【発明の属する技術分野】本発明は、アミラーゼ活性お
よびアルコール脱水素酵素活性を有する担子菌を用い
た、清酒の製法およびそれにより得られた清酒に関する
ものである。TECHNICAL FIELD The present invention relates to a method for producing sake using basidiomycetes having an amylase activity and an alcohol dehydrogenase activity, and the sake produced thereby.
【0002】[0002]
【従来の技術】従来より、清酒の製造には、デンプンの
糖化を行わせる目的で、こうじ菌(こうじかび)が用い
られ、またアルコール発酵を行わせる目的で、酵母が用
いられている。清酒は、一般に、蒸し米をこうじ菌で糖
化しながら、酵母によってアルコール発酵したものであ
る。例えば、図5に示すフローシートに沿って製造され
ている。すなわち、まず、蒸し米にこうじと水を加え、
これに酵母を増殖させる。これを酒母といい、酒母がで
きると、蒸し米,こうじ,水を3回にわたって加え、約
1カ月間発酵させる。この間に、デンプンの糖化とアル
コール発酵が行われる。そして、発酵が終了した熟成も
ろみを、圧搾,おり引き,火入れ殺菌することにより、
清酒が得られる。2. Description of the Related Art Conventionally, in the production of sake, koji mold has been used for the purpose of saccharifying starch, and yeast has been used for the purpose of alcohol fermentation. Sake is generally produced by alcoholic fermentation of yeast with yeast while saccharifying steamed rice with Koji mold. For example, it manufactured along the flow sheet shown in FIG. That is, first add koji and water to steamed rice,
Yeast is grown on this. This is called liquor, and when liquor is formed, steamed rice, koji and water are added 3 times and fermented for about 1 month. During this time, saccharification of starch and alcoholic fermentation are performed. Then, by squeezing, orienting, and sterilizing by burning, the aged moromi that has completed fermentation
You can get sake.
【0003】[0003]
【発明が解決しようとする課題】このように、清酒は、
従来より、アルコール発酵能を有する酵母を用いて製造
されるが、酵母以外の菌を用いて製造した報告は殆どな
く、特に担子菌については全く報告がないといっても過
言ではない。また、酵母は好気条件下におけるアルコー
ル発酵能が小さいため、清酒の製造条件に制限が課せら
れている。さらに、酵母を用いて製造した清酒には、抗
がん性物質であるβ−D−グルカンが殆ど存在せず、し
かも心筋梗塞や脳血栓等の血栓症予防効果も期待できな
い。[Problems to be Solved by the Invention]
Conventionally, it is produced using a yeast having an alcohol fermentation ability, but there is almost no report that it is produced using a bacterium other than yeast, and it is no exaggeration to say that there is no report on basidiomycetes at all. Moreover, since yeast has a small alcohol fermentation ability under aerobic conditions, there are restrictions on the conditions for producing sake. Furthermore, sake produced using yeast hardly contains β-D-glucan, which is an anticancer substance, and cannot be expected to have a thrombosis preventive effect such as myocardial infarction and cerebral thrombosis.
【0004】本発明は、このような事情に鑑みなされた
もので、清酒の製造における糖化工程や発酵工程におい
て、こうじ菌や酵母に代えて、担子菌を用いる、全く新
規な清酒の製法およびそれによって得られる清酒の提供
をその目的とする。The present invention has been made in view of such circumstances, and in the saccharification step and fermentation step in the production of sake, a completely new method for producing sake using basidiomycetes in place of koji mold and yeast, and a method thereof. The purpose is to provide sake obtained by.
【0005】[0005]
【課題を解決するための手段】上記の目的を達成するた
め、本発明は、清酒の製造における発酵工程において、
アミラーゼ活性およびアルコール脱水素酵素活性を有す
る担子菌によってアルコール発酵を行う清酒の製法を第
1の要旨とする。In order to achieve the above object, the present invention provides a fermentation step in the production of sake.
The first gist is a method for producing sake by carrying out alcohol fermentation with basidiomycetes having amylase activity and alcohol dehydrogenase activity.
【0006】また、本発明は、清酒の製造における糖化
工程および発酵工程において、アミラーゼ活性およびア
ルコール脱水素酵素活性を有する担子菌によってデンプ
ンの糖化とアルコール発酵を行う清酒の製法を第2の要
旨とする。The second aspect of the present invention is a method for producing sake, which comprises saccharifying starch and performing alcohol fermentation by a basidiomycete having amylase activity and alcohol dehydrogenase activity in the saccharification step and fermentation step in the production of sake. To do.
【0007】そして、本発明は、上記清酒の製法によっ
て得られる清酒を第3の要旨とする。The third aspect of the present invention is the sake obtained by the above method for producing sake.
【0008】本発明者らは、有用な生理活性物質を産出
する担子菌について、各種の実験研究を重ねていた。そ
の過程で、従来、担子菌はアルコール発酵能がないと思
われていたが、多種の担子菌のうち、アミラーゼ活性お
よびアルコール脱水素酵素活性を備えたものが存在する
ことを見いだした。そして、このような担子菌によって
アルコール発酵またはデンプンの糖化を行い、清酒の製
造を試みた結果、従来と同程度のアルコール度数を有す
る清酒が得られることを突き止め、本発明に到達した。
また、こうじ菌および酵母の2種の微生物によって行っ
ていたデンプンの糖化とアルコール発酵を、上記担子菌
のみで行い、清酒が製造できることを突き止め、本発明
に到達した。The present inventors have conducted various experimental studies on basidiomycetes which produce useful physiologically active substances. In the process, basidiomycetes were conventionally considered to have no alcohol fermenting ability, but it was found that among various types of basidiomycetes, ones having amylase activity and alcohol dehydrogenase activity exist. Then, as a result of trying alcohol production or saccharification of starch with such basidiomycetes to produce sake, it was found that sake having the same alcohol content as the conventional one was obtained, and the present invention was reached.
Further, the inventors have found that sake can be produced by performing saccharification and alcohol fermentation of starch, which has been carried out by two kinds of microorganisms, Koji mold and yeast, and found out that sake can be produced, and arrived at the present invention.
【0009】上記担子菌を用いれば、従来の清酒の製造
と同様、嫌気条件下で清酒を製造することができ、また
好気条件下であっても清酒を製造することができる。そ
のため、清酒の製造条件の緩和が図れるという利点があ
る。嫌気条件の場合は、従来の製造設備をそのまま利用
することができ、新規設備を増設等することなく清酒の
製造が行えるという利点がある。By using the above-mentioned basidiomycetes, sake can be produced under anaerobic conditions as in conventional production of sake, and also under aerobic conditions. Therefore, there is an advantage that the production conditions of sake can be relaxed. In the case of anaerobic conditions, conventional manufacturing equipment can be used as it is, and there is an advantage that sake can be manufactured without adding new equipment.
【0010】そして、本発明の清酒は、従来から用いら
れている酵母ではなく、特定の担子菌によって製造され
たものであるため、酵母では産出できない有用生理活性
物質を含有したものとなる。すなわち、抗腫瘍性,免疫
活性,抗アレルギー性,食物繊維効果を発揮するβ−D
−グルカンや、食物繊維効果を発揮するキチン質,ヘテ
ロ多糖〔ペクチン質,ヘミセルロース,活性ヘミセルロ
ース複合体(AHCC,Active hemicellulose comple
x),ポリウロナイド,リグニン〕等を含有するものと
なる。したがって、本発明の清酒は、従来にはない全く
新規なものとなり、機能性・健康飲料となりうる。Since the sake of the present invention is produced by a specific basidiomycete, not by the yeast which has been conventionally used, it contains a useful physiologically active substance which cannot be produced by yeast. That is, β-D that exhibits antitumor properties, immunoreactivity, antiallergic properties, and dietary fiber effects
-Glucan, chitin, heteropolysaccharide [pectin, hemicellulose, active hemicellulose complex (AHCC, Active hemicellulose comple
x), polyuronide, lignin] and the like. Therefore, the sake of the present invention becomes a completely new one that has never been obtained before and can be a functional and healthy beverage.
【0011】なお、本発明において、担子菌とは、子実
体が「きのこ」といわれているものをいい、微生物分類
学上の担子菌類(ハラタケ類,ヒダナシタケ類,腹菌
類,キクラゲ類)のほか、子のう菌類の一部をも含む概
念で用いている。In the present invention, the basidiomycete means that the fruiting body is referred to as a "mushroom", and in addition to basidiomycetes in the taxonomic classification of microorganisms (Agaricales, Hydrangea mushrooms, Abdominal fungi, Fungus fungi). , The concept also includes some of the ascomycetes.
【0012】また、本発明において、嫌気条件下とは、
酸素分圧が1.0kPa未満である条件下をいい、完全
に酸素がない状態も含まれる。一方、好気条件とは、酸
素分圧が1.0kPa以上である条件下をいう。In the present invention, the anaerobic condition means
It means the condition that the oxygen partial pressure is less than 1.0 kPa, and also includes the condition where there is no oxygen. On the other hand, the aerobic condition means a condition that the oxygen partial pressure is 1.0 kPa or more.
【0013】[0013]
【発明の実施の形態】つぎに、本発明の実施の形態につ
いて説明する。BEST MODE FOR CARRYING OUT THE INVENTION Next, embodiments of the present invention will be described.
【0014】本発明の清酒の製法は、従来公知の各種の
清酒の製法における糖化工程、発酵工程において、従来
から一般に用いられているこうじ菌や酵母を使用するの
ではなく、特定の担子菌を用い、この担子菌によって、
デンプンの糖化、アルコール発酵を行うものである。The sake brewing method of the present invention uses a specific basidiomycete in the saccharification step and fermentation step of various conventionally known sake brewing methods, instead of using Koji mold or yeast which has been generally used. Used by this basidiomycete,
Saccharification of starch and alcoholic fermentation are performed.
【0015】本発明で用いられる特定の担子菌として
は、アミラーゼ活性およびアルコール脱水素酵素活性を
有するものであれば特に限定はなく、例えば、各地の森
林等で採取される、アガリクスタケ(Agaricus blazei
,アガリクス ブラゼイ)、ヒラタケ(Pleurotus ost
reatus ,プレロトス オストレタス)、エノキタケ(F
lammulina velutipes,フラムリナ ベルチペス)、マ
ツタケ(Tricholoma matsutake,トリコロマ マツタ
ケ)、キクラゲ(Auricularia auricula,アリキュラリ
ア アリキュラ)、クリタケ(Naematoloma sublaterit
ium ,ナエマトロマスブラテリチュム)、シイタケ(Le
ntinus edodes ,レンチナス エドデス)、ショウロ
(Rhizopogon rubescens,リゾポゴン ルベセンス)、
スエヒロタケ(Schizophyllum commune ,シゾフィラム
コムネ)、タモギタケ(Pleurotus citrinopileatus
,プレロトス シトリノピレタス)、チョウレイマイ
タケ(Dendropolyporus umbellatus,デンドロポリポル
ス ウベラタス)、ブクリョウ(Poria cocos ,ポリア
ココス)、ブナシメジ(Hypsizygus marmoreus,ヒプ
シジガス マルモレス)、マイタケ(Grifola frandos
a,グリフォラ フランドサ)、マスタケ(Laetiporus
sulphureus ,ラエチポラス スルフレス)、マンネン
タケ(Ganoderma lucidum ,ガノデルマ ルシダム)、
ツクリタケ(Agaricus bisporus ,アガリクス ビスポ
ラス)、ヤナギマツタケ(Agrocybe cylindracea,アグ
ロシベ シリンドラセア)、ヤマブシタケ(Hericium e
rinaceum,ヘリシウム エリナセム)、カワラタケ(Co
riolus versicolor ,コリオルス ヴャジカラア)、コ
フキサルノコシカケ(Elfvingia applanata ,エルフィ
ンギア アプラナタ)、ナメコ(Pholiota nameco ,ポ
リオタ ナメコ)、ヌメリスギタケ(Pholiota adipos
a,ポリオタ アディポサ)、アミガサタケ(Morchella
esculenta ,モルシェラ エスキュレンタ)、キシメ
ジ(Tricholoma flavovireus,トリコロマ フラボビレ
ス)、シロハツ(Russula delica,ルシュラ デリ
カ)、ツガサルノコシカケ(Fomitopsis pinicola ,フ
ォミトシス ピニコラ)、ノウタケ(Calvatia craniif
ormis ,カルバチア クラニフォルミス)、ハエヤドリ
タケ(Cordyceps dipterigene ,コルディセプス ディ
テリゲナ)、ホウキタケ(Ramaria botrytis,ラマリア
ボトリチス)、マツタケモドキ(Tricholomarobustum
,トリコロマ ロブスタン)、ムラサキシメジ(Lepis
ta nuda,レピスタ ヌダ)、ヤマイグチ(Leccinum sc
abrum,レシナム スカブラン)、クロハツ(Russula n
igricans ,ルッスラ ニグリカンス)、ハタケシメジ
(Lyophyllum decastes ,リョフィラム デカステ
ス)、ヤマドリタケ(Boletus edulis,ボレタス エド
ュリス)等があげられる。なかでも、入手容易性や、ア
ルコール脱水素酵素活性、アミラーゼ活性等を考慮し
て、アガリクスタケ、マツタケ、ブナシメジが好適であ
る。ブナシメジを用いれば、芳醇な味と香りの清酒が製
造されるだけでなく、種々の生理活性物質が清酒中に含
まれるという利点がある。The specific basidiomycete used in the present invention is not particularly limited as long as it has amylase activity and alcohol dehydrogenase activity, and for example, Agaricus blazei collected in forests in various places.
, Agaricus blazei), Pleurotus ost
reatus, Plerotos ostretas), Enoki mushroom (F
lammulina velutipes, Flamlina velutipes, Tricholoma matsutake, Auricularia auricula, Auricularia auricula, Naematoloma sublaterit
ium, Naematromas bratericum), shiitake mushroom (Le
ntinus edodes, Lentinas eddes), Shoro (Rhizopogon rubescens, Rhizopogon rubesense),
Pleurotus citrinopileatus, Schizophyllum commune, Pleurotus citrinopileatus
, Plerotus citrinopyretas), Ganoderma lucidum (Dendropolyporus umbellatus, Dendropolyporus uberatas), Bukuro (Poria cocos, Polyacokos), Beech shimeji (Hypsizygus marmoreus, Hypsizygus marmores), Maitake (Grifola frandos)
a, Gryphora frandosa), Mustache (Laetiporus)
sulphureus, Laetiporus sulfures), Ganoderma lucidum (Ganoderma lucidum),
Agaricus bisporus (Agaricus bisporus, Agaricus bisporus), willow matsutake (Agrocybe cylindracea, Aguroshibe cylindracea), mountain blanking Shitake (Hericium e
rinaceum, Helicinium Erinathem), Kawatake (Co)
riolus versicolor, Coriolus vyadicara, Elfvingia applanata, Elfingia aplanata, Nameko, Pholiota nameco, Pholiota adipos
a, Poliota adiposa), Morel mushroom (Morchella)
esculenta, Morcella esculenta, Ximezie (Tricholoma flavovireus, Tricoloma flavoviles), White beetle (Russula delica, Rusula delica), Fugatopsis pinicola, Phomitosis pinicola, Noutake (Calvatia craniif)
ormis, Carbachia claniformis), Flycatcher (Cordyceps dipterigene, Cordyceps diterrigena), Houkitake (Ramaria botrytis, Lamaria botrytis), Tricholoma robustum
, Torikorama Robustan), Murasakishimeji (Lepis)
ta nuda, Lepista Nuda), Yamaguchi (Leccinum sc)
abrum, Reshinam Sukablan), Black Shrimp (Russula n)
igricans, russula niglycans), Hatake shimeji (Lyophyllum decastes), Yamadoritake (Boletus edulis, Boretas edulis) and the like. Of these, agaricus mushroom, matsutake mushroom, and beech shimeji mushroom are preferable in consideration of availability, alcohol dehydrogenase activity, amylase activity, and the like. Using Buna-shimeji has the advantage that not only is sake with a rich taste and aroma produced, but also various physiologically active substances are contained in sake.
【0016】そして、上記特定の担子菌におけるアミラ
ーゼ活性は、例えば、つぎのようにして確認することが
できる。すなわち、まず、可溶性デンプン2.5重量%
を溶 解した5mMCaCl 2 を含む50mM酢酸緩衝液
を調製し、これを基質溶液とする。つぎに、基質溶液3
00μlに粗酵素液100μlを加え、40℃で5分間
反応させる。酵素反応は、沸騰湯中で10分間加熱して
停止させる。反応停止後、反応液に1.0mlの0.5
N酢酸と0.1%ヨウ素液3.0mlを加え、よく攪拌
してからダブルビーム分光光度計で700nmでの吸光
度を測定し、この値が、初期値(ブランク、粗酵素液に
代えて水を用いて測定した値)から減少しておれば、ア
ミラーゼ活性を有するものであるといえる。なお、先に
列挙した担子菌であっても、上記アミラーゼ活性が確認
されないものは、本発明において用いることはできな
い。 And amira in the above specific basidiomycete
The enzyme activity can be confirmed, for example, as follows.
it can. That is, first, soluble starch 2.5% by weight
50mM acetate buffer containing 5 mM CaCl 2 was dissolve the
Is prepared and used as a substrate solution. Next, the substrate solution 3
Add 100 μl of crude enzyme solution to 00 μl, and for 5 minutes at 40 ° C.
React. Enzyme reaction is heated in boiling water for 10 minutes
Stop. After stopping the reaction, add 1.0 ml of 0.5 to the reaction solution.
Add 3.0 ml of N-acetic acid and 0.1% iodine solution and stir well
And then using a double beam spectrophotometer to absorb at 700 nm
The initial value (blank, crude enzyme solution
If the value is less than the value measured using water instead,
It can be said to have a millase activity. In addition, first
The above amylase activity was confirmed even in the listed basidiomycetes
Those which are not used cannot be used in the present invention.
Yes.
【0017】また、上記特定の担子菌におけるアルコー
ル脱水素酵素活性の有無は、例えば、つぎのようにして
確認することができる。すなわち、まず、担子菌に対し
超音波処理,遠心分離処理を行い、上清液を粗酵素液と
して調製する。また、0.1Mトリス緩衝液(pH7.
4)12.5mlと、NAD + 0.1mlと、0.1M
エタノール11.0mlと、フェナジンメトサルフェー
ト(PMS)0.5mlと、ニトロブルーテトラゾリウ
ム(NBT)0.5mlと、水10mlとを配合して混
合することにより、反応溶液を調製する。つぎに、上記
粗酵素液0.02mlを用い、ポリアクリルアミドゲル
電気泳動を行った後、そのポリアクリルアミドゲルを上
記反応溶液に浸し、30℃で1時間反応させる。そし
て、染色されたアルコール脱水素酵素のバンドが確認で
きれば、アルコール脱水素酵素活性があるものであると
いえる。なお、先に列挙した担子菌であっても、上記ア
ルコール脱水素酵素活性が確認されないものは、本発明
において用いることはできない。 Further , the alcohol in the above specific basidiomycete
The presence or absence of dehydrogenase activity can be determined, for example, as follows.
You can check. That is, first, for basidiomycetes
Ultrasonication and centrifugation are performed, and the supernatant is used as the crude enzyme solution.
And prepare. In addition, 0.1 M Tris buffer (pH 7.
4) 12.5 ml , NAD + 0.1 ml, 0.1M
11.0 ml of ethanol and phenazine methsulfate
(PMS) 0.5 ml and nitro blue tetrazoliu
0.5 ml (NBT) and 10 ml of water are mixed and mixed.
A reaction solution is prepared by combining. Next, above
Using 0.02 ml of crude enzyme solution, polyacrylamide gel
After electrophoresis, run the polyacrylamide gel on top.
Immerse in the above reaction solution and react at 30 ° C. for 1 hour. That
Then, the stained alcohol dehydrogenase band can be confirmed.
If it comes, it means that it has alcohol dehydrogenase activity.
I can say. Even if the basidiomycetes listed above are used,
If the rucor dehydrogenase activity is not confirmed, the present invention
Cannot be used in.
【0018】そして、上記担子菌のなかでも、アルコー
ル脱水素酵素活性が1.0units/mg以上のもの
が好適であり、特に10.0units/mg以上のも
のが最適である。すなわち、アルコール脱水素酵素活性
が低すぎると、担子菌を多量に使用する等の手段を講じ
なければならず、清酒の製造上好ましいとはいえないか
らである。なお、アルコール脱水素酵素活性は、担子菌
を超音波処理,遠心分離処理したのちに得られる上清液
を粗酵素液として用い、エタノールとトリス緩衝液とN
AD+ 等を用い、NADHの示す340nmにおける吸
光度を測定することにより求められる。Among the above-mentioned basidiomycetes, those having an alcohol dehydrogenase activity of 1.0 units / mg or more are preferable, and those having 10.0 units / mg or more are most preferable. That is, if the alcohol dehydrogenase activity is too low, it is necessary to take measures such as using a large amount of basidiomycetes, which is not preferable in the production of sake. The alcohol dehydrogenase activity was determined by using a supernatant obtained after sonication and centrifugation of basidiomycetes as a crude enzyme solution, ethanol, Tris buffer and N.
It can be obtained by measuring the absorbance of NADH at 340 nm using AD + or the like.
【0019】本発明の清酒の製造は、つぎのあるいは
の方法に大別される。The production of sake according to the present invention is as follows.Or
The methods are roughly classified.
【0020】 清酒の製造における糖化工程について
は、従来と同様、こうじ菌によってデンプンの糖化を行
い、発酵工程については、アミラーゼ活性およびアルコ
ール脱水素酵素活性を有する担子菌によってアルコール
発酵を行う製法。In the saccharification step in the production of sake, starch is saccharified by Koji mold as in the conventional method, and in the fermentation process, alcohol fermentation is performed by basidiomycetes having amylase activity and alcohol dehydrogenase activity.
【0021】 清酒の製造における糖化工程と発酵工
程の両工程とも、アミラーゼ活性およびアルコール脱水
素酵素活性を有する担子菌によってデンプンの糖化とア
ルコール発酵とを行う製法。Saccharification process and fermentation process in the production of sake
In both of the above steps, a method of saccharifying starch and alcohol fermentation with a basidiomycete having an amylase activity and an alcohol dehydrogenase activity.
【0022】上記製法の一例について、図1に示すフ
ローシートに沿って説明する。すなわち、まず、蒸し米
にこうじと水を加え、これに上記担子菌を1〜10重量
%程度加えて増殖させ、酒母を作る。担子菌は、純粋培
養したものを液体培養し、菌糸体として生育させたもの
を用いることが好ましい。ついで、酒母に、蒸し米,こ
うじ,水を3回にわたって加え、約1カ月間、嫌気条件
下で発酵させる。この間に、こうじ菌および上記担子菌
によるデンプンの糖化(糖化工程)と、上記担子菌によ
るアルコール発酵(発酵工程)が行われる。その後、従
来の清酒の製法と同様、発酵が終了した熟成もろみを、
圧搾,おり引き,火入れ殺菌の各工程を経由させ、びん
等の容器に詰めることにより、上記担子菌のみによって
アルコール発酵が行われた清酒が得られる。An example of the above manufacturing method will be described with reference to the flow sheet shown in FIG. That is, first, koji and water are added to steamed rice, and about 1 to 10% by weight of the above basidiomycete is added to the steamed rice to grow the steamed rice to make a sake mother. As the basidiomycete, it is preferable to use a pure culture that is liquid-cultured and grown as a mycelium. Then, steamed rice, koji, and water are added to the sake mother three times, and the fermentation is performed under anaerobic conditions for about one month. During this period, saccharification of starch by Koji mold and the above basidiomycete (saccharification process) and alcoholic fermentation by the above basidiomycete (fermentation process) are performed. After that, as in the conventional sake production method, the fermented moromi mash,
By passing through the steps of squeezing, dropping, and sterilization by burning, it is packed in a container such as a bottle to obtain sake which has been subjected to alcohol fermentation only by the above basidiomycetes.
【0023】また、上記製法 の一例について、図2に
示すフローシートに沿って説明する。すなわち、まず、
蒸し米に上記担子菌を1〜10重量%程度加えてきのこ
こうじ(担子菌を生育させたもの)をつくり、このきの
ここうじと蒸し米と水とを混合して担子菌を増殖させ、
酒母を作る。ついで、酒母に、蒸し米,きのここうじ,
水を3回にわたって加え、約1カ月間、嫌気条件下で発
酵させる。この間に、上記担子菌によるデンプンの糖化
(糖化工程)とアルコール発酵(発酵工程)が行われ
る。すなわち、従来の並行複発酵ではなく、単行発酵が
行われる。その後、従来の清酒の製法と同様、発酵が終
了した熟成もろみを、圧搾,おり引き,火入れ殺菌の各
工程を経由させ、びん等の容器に詰めることにより、上
記担子菌のみによってデンプンの糖化とアルコール発酵
が行われた清酒が得られる。Further, the above manufacturing method Figure for an exampleTwoTo
A description will be given along the flow sheet shown. That is, first,
Boiled rice with about 1-10% by weight of Basidiomycetes
We make koji (thing which let Basidiomycete grow) and make mushroom
Kokouji, steamed rice and water are mixed to grow basidiomycetes,
Make a liquor mother. Then, for the sake mother, steamed rice, mushroom mushrooms,
Water was added 3 times, and it was emitted under anaerobic conditions for about 1 month.
Ferment. During this period, saccharification of starch by the above-mentioned basidiomycetes
(Saccharification process) and alcoholic fermentation (fermentation process)
It In other words, single fermentation is not the conventional parallel multiple fermentation
Done. After that, fermentation is completed as in the conventional sake production process.
Finished aged moromi is squeezed, squeezed, and sterilized by burning.
By passing through the process and packing in containers such as bottles,
Saccharification and alcoholic fermentation of starch only by Bacillus subtilis
You can get the sake.
【0024】このようにして得られた清酒は、上記担子
菌のアルコール発酵により製造されたものであるため、
担子菌由来の生理活性物質であるβ−D−グルカン等を
含有したものとなる。このため、上記清酒を飲むと、が
ん予防効果、広範囲にわたる疫病予防効果、アレルギー
予防効果(アトピーに有効)、食物繊維効果等が得られ
る。また、担子菌の種類によっては、血栓を溶かす作用
がある線溶酵素、血栓を作りにくくする抗トロンビン活
性物質を含有したものとなり、心筋梗塞や脳血栓等の血
栓症予防効果が得られる。さらに、エルゴステロール
(プロビタミンD2 )を含有したものとなったり、抗菌
活性(保存性を高める)を発揮するものとなる。そし
て、シイタケを用いた場合には、高血圧や高コレステロ
ール症予防効果があるエリタデニンを含有したものとな
り、マンネンタケを用いた場合には、血糖降下作用があ
る多糖ガノデランを含有したものとなり、エノキタケを
用いた場合には、強心作用があるフラムトキシンを含有
したものとなり、ヤマブシタケを用いた場合には、痴呆
症改善効果がある神経成長因子を含有したものとなる。
また、マイタケを用いた場合には、コレステロール値,
中性脂肪,血糖値,尿糖値を減少させる血圧降下作用を
奏するものとなり、ヒラタケを用いた場合には、摂食抑
制活性(レクチン活性)を発揮するものとなる。The sake thus obtained is produced by alcoholic fermentation of the above basidiomycetes,
The product contains β-D-glucan, which is a physiologically active substance derived from basidiomycete. Therefore, when the above-mentioned sake is drunk, a cancer preventive effect, a widespread disease preventive effect, an allergy preventive effect (effective for atopy), a dietary fiber effect, etc. can be obtained. Further, depending on the type of basidiomycete, a fibrinolytic enzyme having an action of dissolving a thrombus and an antithrombin active substance that makes it difficult to form a thrombus are contained, and a thrombosis preventive effect such as myocardial infarction or cerebral thrombosis can be obtained. Further, it becomes a substance containing ergosterol (provitamin D 2 ) or exhibits antibacterial activity (improves preservability). And, when shiitake is used, it contains erytadenine, which has the effect of preventing hypertension and hypercholesterolemia, and when mannemtake is used, it contains polysaccharide ganodelan, which has a hypoglycemic effect. When it is present, it contains flamtoxin which has a cardiotonic action, and when it is used, it contains a nerve growth factor which has a dementia-improving effect.
When using Maitake, the cholesterol level,
It exerts a blood pressure lowering action to reduce neutral fat, blood glucose level and urinary glucose level, and when oyster mushroom is used, it exerts antifeedant activity (lectin activity).
【0025】また、上記清酒は、特定の担子菌を用いて
製造されたものであるが、従来の清酒と同程度のアルコ
ール度数を有するものとなる。しかも、従来の清酒の風
味にはないきのこ風味が付与されたものとなり、嗅覚的
にも全く新規なものとなる。さらに、味覚的には、芳醇
な味となり、担子菌のほのかな味が加わり、全く新規な
ものとなる。The above-mentioned sake is produced by using a specific basidiomycete, but has the same alcohol content as conventional sake. Moreover, a mushroom flavor that is not present in the flavor of conventional sake is imparted, and the flavor is completely novel. Furthermore, in terms of taste, the taste becomes rich, and the faint taste of basidiomycete is added, resulting in a completely new taste.
【0026】また、上記製法であれば、従来の清酒の
製法において用いられていた酵母を上記特定の担子菌に
代えるだけで済むため、従来の製造設備をそのまま利用
することができ、新規設備を増設等することなく清酒の
製造を行うことができる。Further, if the above process, because it requires a yeast that has been used in the preparation of conventional sake just substituted for the specific basidiomycete, can be used as it is conventional manufacturing equipment, new equipment It is possible to produce sake without adding more.
【0027】そして、上記製法 であれば、清酒の製造
を単行発酵で行うことができるため、製造効率の向上が
実現でき、生産性の向上が期待できる。And the above-mentioned manufacturing method Then, the production of sake
Since it can be carried out by single-row fermentation, the production efficiency can be improved.
It can be realized and productivity can be expected to improve.
【0028】なお、上記製法では、嫌気条件下で発酵工
程を行った例を説明したが、本発明の清酒の製法はこれ
に限定するものではなく、好気条件下で発酵を行うこと
も可能である。上記特定の担子菌は、好気条件下におい
てもアルコール発酵を行うことができるからである。In the above production method, an example in which the fermentation step was carried out under anaerobic conditions was explained, but the production method of sake according to the present invention is not limited to this, and fermentation can be carried out under aerobic conditions. Is. This is because the specific basidiomycete can perform alcoholic fermentation even under aerobic conditions.
【0029】つぎに、実施例について比較例と併せて説
明する。Next, examples will be described together with comparative examples.
【0030】[0030]
【実施例1】図2に示すフローシートに準じて、つぎの
ようにして清酒の製造を行った。すなわち、まず、精米
を準備し、これを蒸したものに担子菌であるアガリクス
タケ〔ブラジル産(直輸入)のアガリクスタケ、永大薬
業社製〕約5重量%(全蒸し米に対して)を加え、室温
(20℃),15日間の条件で生育させ、きのここうじ
(担子菌を生育させたもの)を作った。ついで、得られ
たきのここうじの一部と蒸し米と水とを混合して酒母と
し、これに、きのここうじの残部,蒸し米,水を3回に
わたって加え、1カ月間、嫌気条件下で、デンプンの糖
化とアルコール発酵とを行った。このようにして、目的
とする清酒の製造を行った。アルコール度数は、8.0
%であった。Example 1 Sake was produced according to the flow sheet shown in FIG. 2 as follows. That is, first, prepared rice milled and steamed to prepare a basidiomycete Agarikustake [Brazil (directly imported) Agarikustake, manufactured by Eidai Pharmaceutical Co., Ltd.] about 5% by weight (for all steamed rice) ) Was added and the mixture was grown at room temperature (20 ° C.) for 15 days to prepare mushroom kouji (a basidiomycete was grown). Then, a part of the obtained mushroom koji, steamed rice, and water are mixed to make a liquor, and the rest of mushroom koji, steamed rice, and water are added to this three times, and for 1 month under anaerobic conditions, Saccharification of starch and alcoholic fermentation were performed. In this way, the intended sake was produced. Alcohol content is 8.0
%Met.
【0031】[0031]
【実施例2】デンプンの糖化とアルコール発酵を好気条
件下で行う以外は、実施例1と同様にして、清酒を製造
した。アルコール度数は、8.0%であった。Example 2 Sake was produced in the same manner as in Example 1 except that saccharification of starch and alcohol fermentation were carried out under aerobic conditions. The alcohol content was 8.0%.
【0032】[0032]
【実施例3】担子菌としてマスタケ(滋賀県足尾谷で採
取)を用いる以外は、実施例1と同様にして、清酒を製
造した。[Example 3] Sake was produced in the same manner as in Example 1 except that Mustake (collected in Ashioya, Shiga Prefecture) was used as the basidiomycete.
【0033】[0033]
【実施例4】担子菌としてマスタケ(滋賀県足尾谷で採
取)を用い、好気条件下でアルコール発酵を行う以外
は、実施例1と同様にして、清酒を製造した。[Example 4] Sake was produced in the same manner as in Example 1 except that Mustake (collected in Ashioya, Shiga Prefecture) was used as a basidiomycete and alcohol fermentation was performed under aerobic conditions.
【0034】[0034]
【実施例5】担子菌としてマツタケ(丹波篠山で採取)
を用いる以外は、実施例1と同様にして、清酒を製造し
た。[Example 5] Matsutake as a basidiomycete (collected at Tanba Sasayama)
Sake was produced in the same manner as in Example 1 except that
【0035】[0035]
【実施例6】担子菌としてマツタケ(丹波篠山で採取)
を用い、好気条件下でアルコール発酵を行う以外は、実
施例1と同様にして、清酒を製造した。[Example 6] Matsutake as a basidiomycete (collected at Tanba Sasayama)
Sake was produced in the same manner as in Example 1 except that alcoholic fermentation was carried out under aerobic conditions.
【0036】[0036]
【実施例7】担子菌としてブナシメジ(Superやま
びこしめじ、JA長野経済連)を用いる以外は、実施例
1と同様にして、清酒を製造した。EXAMPLE 7 beech Shi joint (Super Yamabiko shimeji, JA Keizairen Nagano) as basidiomycete except for using, in the same manner as in Example 1, was prepared sake.
【0037】[0037]
【実施例8】担子菌としてブナシメジ(Superやま
びこしめじ、JA長野経済連)を用い、好気条件下でア
ルコール発酵を行う以外は、実施例1と同様にして、清
酒を製造した。[Example 8] Sake was produced in the same manner as in Example 1 except that Buna shimeji (Super or Mabiko Shimeji, JA Nagano Keizai Ren) was used as a basidiomycete and alcohol fermentation was performed under aerobic conditions.
【0038】[0038]
【実施例9】図1に示すフローシートに準じて、つぎの
ようにして清酒の製造を行った。すなわち、まず、精米
を準備し、これを蒸したものに、こうじかびを加えてこ
うじを作り、蒸し米に、担子菌であるアガリクスタケ
〔ブラジル産(直輸入)のアガリクスタケ、永大薬業社
製〕約5重量%(全蒸し米に対して)とこうじと水とを
加え、酒母を作った。ついで、この酒母に、蒸し米,こ
うじ,水を3回にわたって加え、1カ月間、嫌気条件下
で、デンプンの糖化とアルコール発酵とを行った。この
ようにして、目的とする清酒の製造を行った。アルコー
ル度数は、8.0%であった。Example 9 Sake was produced in the following manner according to the flow sheet shown in FIG. In other words, first, we prepare milled rice, add steamed koji mold to steamed rice to make koji, and add steamed rice to the basidiomycete Agarikustake (Brassica (direct import) Agarikustake, Eidai Pharmaceutical Industry). Made by the company] About 5% by weight (based on all steamed rice), koji and water were added to make a sake mother. Then, steamed rice, koji, and water were added to this liquor mother three times, and saccharification of starch and alcohol fermentation were performed for 1 month under anaerobic conditions. In this way, the intended sake was produced. The alcohol content was 8.0%.
【0039】[0039]
【比較例】比較例として、市販の清酒(キング醸造社
製、のほほん、アルコール度数13.5%)を準備し
た。Comparative Example As a comparative example, commercially available sake (manufactured by King Brewing Co., Noho, alcohol content 13.5%) was prepared.
【0040】このようにして得られた実施例および比較
例の清酒について、下記に示すようにして、アミラーゼ
活性、アルコール脱水素酵素活性、β−D−グルカンの
有無、線溶活性、抗トロンビン活性の測定評価を行っ
た。そして、その結果を、後記の表1〜表3に示した。With respect to the sake thus obtained in Examples and Comparative Examples, the amylase activity, alcohol dehydrogenase activity, the presence or absence of β-D-glucan, fibrinolytic activity and antithrombin activity were determined as follows. Was measured and evaluated. The results are shown in Tables 1 to 3 below.
【0041】〔アミラーゼ活性〕
まず、可溶性デンプン2.5重量%を溶解した5mMC
aCl2 を含む50mM酢酸緩衝液を調製し、これを基
質溶液とした。つぎに、基質溶液300μlに粗酵素液
100μlを加え、40℃で5分間反応させた。酵素反
応は、沸騰湯中で10分間加熱して停止させた。反応停
止後、反応液に1.0mlの0.5N酢酸と0.1%ヨ
ウ素液3.0mlを加え、よく攪拌してからダブルビー
ム分光光度計で700nmでの吸光度を測定した。そし
て、Abs(700nm)の値が、初期値(ブランク、
粗酵素液に代えて水を用いて測定した値)の0.400
から減少しておればアミラーゼ活性を有しているとして
○、0.400から減少しなければアミラーゼ活性を有
していないとして×と評価した。例えば、アガリクスタ
ケの粗酵素液(実施例1)では0.049まで減少し、
マツタケの粗酵素液(実施例5)では0.148まで減
少するため、それぞれアミラーゼ活性を有していること
が確認できる。[Amylase activity] First, 5 mM C in which 2.5% by weight of soluble starch was dissolved
A 50 mM acetate buffer containing aCl 2 was prepared and used as a substrate solution. Next, 100 μl of the crude enzyme solution was added to 300 μl of the substrate solution and reacted at 40 ° C. for 5 minutes. The enzymatic reaction was stopped by heating in boiling water for 10 minutes. After the reaction was stopped, 1.0 ml of 0.5 N acetic acid and 3.0 ml of 0.1% iodine solution were added to the reaction solution, and the mixture was stirred well and then the absorbance at 700 nm was measured with a double beam spectrophotometer. Then, the value of Abs (700 nm) is the initial value (blank,
0.400) (value measured using water in place of the crude enzyme solution)
It was evaluated as having an amylase activity when it decreased from 0, and evaluated as having no amylase activity when not decreasing from 0.400. For example, the crude enzyme solution of Agaricus mushroom (Example 1) decreased to 0.049,
Since the crude enzyme solution of Matsutake (Example 5) decreased to 0.148, it could be confirmed that each had amylase activity.
【0042】〔アルコール脱水素酵素活性〕
*1:アルコール脱水素酵素の存在の有無
まず、担子菌に対し超音波処理,遠心分離処理を行い、
上清液を粗酵素液として調製した。また、0.1Mトリ
ス緩衝液(pH7.4)12.5mlと、NAD+ 0.
1mlと、0.1Mエタノール11.0mlと、フェナ
ジンメトサルフェート(PMS)0.5mlと、ニトロ
ブルーテトラゾリウム(NBT)0.5mlと、水10
mlとを配合して混合することにより、反応溶液を調製
した。つぎに、上記粗酵素液0.02mlを用い、ポリ
アクリルアミドゲル電気泳動を行った後、そのポリアク
リルアミドゲルを上記反応溶液に浸し、30℃で1時間
反応させた。そして、染色された活性バンドから、アル
コール脱水素酵素活性の有無を評価した。すなわち、染
色されたアルコール脱水素酵素のバンドが確認できたも
のはアルコール脱水素酵素活性があるものとして○、バ
ンドが確認できなかったものはアルコール脱水素酵素活
性がないものとして×をつけた。
*2:アルコール脱水素酵素活性の測定
まず、上記と同様にして、粗酵素液を調製した。また、
0.25Mトリス緩衝液(pH7.4)0.16ml
と、NAD+ 0.05mlと、0.1Mエタノール0.
1mlと、水0.19mlとを配合して混合することに
より、反応溶液を調製した。つぎに、反応溶液を30℃
に加温し、このなかに予め30℃に加温しておいた粗酵
素液0.05mlを添加し反応させた。そして、340
nmにおける吸光度の経時変化を測定し、吸光度の増加
速度を求めることにより、アルコール脱水素酵素活性
(units/mg) を求めた。なお、1分間に1μm
oleのNAD+ を還元する酵素量を1unitとし
た。[Alcohol dehydrogenase activity] * 1: Presence or absence of alcohol dehydrogenase First, basidiomycetes are subjected to ultrasonic treatment and centrifugal separation treatment,
The supernatant was prepared as a crude enzyme solution. Further, 12.5 ml of 0.1 M Tris buffer (pH 7.4) and NAD + 0.
1 ml, 0.1 M ethanol 11.0 ml, phenazine methosulfate (PMS) 0.5 ml, nitroblue tetrazolium (NBT) 0.5 ml, and water 10
A reaction solution was prepared by blending and mixing with ml. Next, after performing polyacrylamide gel electrophoresis using 0.02 ml of the crude enzyme solution, the polyacrylamide gel was immersed in the reaction solution and reacted at 30 ° C. for 1 hour. Then, the presence or absence of alcohol dehydrogenase activity was evaluated from the stained active band. That is, the one in which a stained alcohol dehydrogenase band was confirmed was marked as having alcohol dehydrogenase activity, and the one in which no band was confirmed was marked as having no alcohol dehydrogenase activity. * 2: Measurement of alcohol dehydrogenase activity First, a crude enzyme solution was prepared in the same manner as above. Also,
0.16 ml of 0.25M Tris buffer (pH 7.4)
, NAD + 0.05 ml, 0.1 M ethanol 0.
A reaction solution was prepared by mixing 1 ml and 0.19 ml of water and mixing them. Next, the reaction solution is heated to 30 ° C.
The reaction mixture was heated to 0.degree. C., and 0.05 ml of the crude enzyme solution which had been heated to 30.degree. And 340
The alcohol dehydrogenase activity (units / mg) was determined by measuring the change with time in absorbance at nm and determining the rate of increase in absorbance. In addition, 1 μm per minute
The amount of ole NAD + reducing enzyme was set to 1 unit.
【0043】〔β−D−グルカンの有無〕
清酒中にβ−D−グルカンが存在するか否かを確認する
ために、高性能液体クロマトグラフィー(HPLC)を
用いてβ−D−グルカンの検出を行った。そして、β−
D−グルカンのピークが認められ清酒中に存在している
ことが確認できたものには○、確認できなかったものに
は×をつけた。なお、図3は、アガリクスタケを用いて
製造した清酒(実施例1)のデータであり、矢印で示す
部分にβ−D−グルカンのピークが存在することを確認
できる。また、図4は、市販の清酒(比較例)のデータ
であり、矢印で示す部分に若干のピークが認められる。
しかし、市販の清酒のデータが示すピークは、酵素(β
−1,3−グルカナーゼ)処理の結果、β−D−グルカ
ンでないことを確認している。[Presence or absence of β-D-glucan] In order to confirm whether or not β-D-glucan is present in sake, detection of β-D-glucan is performed by using high performance liquid chromatography (HPLC). I went. And β-
The peaks of D-glucan were observed, and those confirmed to be present in sake were marked with O, and those not confirmed were marked with X. In addition, FIG. 3 is the data of sake (Example 1) manufactured using Agaricus edulis, and it can confirm that the peak of (beta) -D-glucan exists in the part shown by the arrow. Further, FIG. 4 is data of commercially available sake (comparative example), and some peaks are recognized in the portions indicated by arrows.
However, the peak of the commercially available sake data shows that the enzyme (β
As a result of the (-1,3-glucanase) treatment, it was confirmed that it was not β-D-glucan.
【0044】〔線溶活性〕
フィブリン平板(5671mm2 )の表面に清酒0.0
3mlを円形に散布し(散布面積19.6mm2 )、1
時間放置後の溶解面積を測定した。[Fibrinolytic activity] Sake 0.0 on the surface of a fibrin plate (5671 mm 2 ).
Disperse 3 ml in a circle (spray area 19.6 mm 2 ), 1
The dissolution area after standing for a period of time was measured.
【0045】〔抗トロンビン活性〕
トロンビンの反応でフィブリノゲンからフィブリンに変
化し凝固するまでの時間(トロンビン時間)を測定し
た。すなわち、フィブリノゲン0.13重量%液0.4
mlに対し、清酒0.1mlを作用させ、凝固するまで
の時間を測定した。[Antithrombin activity] The time (thrombin time) until fibrinogen was changed from fibrinogen to fibrin by the reaction of thrombin and coagulation was measured. That is, 0.13% by weight fibrinogen solution 0.4
0.1 ml of sake was applied to ml, and the time until coagulation was measured.
【0046】[0046]
【表1】 [Table 1]
【0047】[0047]
【表2】 [Table 2]
【0048】[0048]
【表3】 [Table 3]
【0049】表1〜表3の結果から、アミラーゼ活性お
よびアルコール脱水素酵素活性を有する担子菌によって
デンプンの糖化およびアルコール発酵させて製造した清
酒(実施例1品〜8品)には、生理活性物質であるβ−
D−グルカンが含まれていることがわかる。また、アミ
ラーゼ活性およびアルコール脱水素酵素活性を有する担
子菌によってアルコール発酵させて製造した清酒(実施
例9品)にも、β−D−グルカンが含まれていることが
わかる。これに対し、市販の清酒(比較例品)には、β
−D−グルカンが含まれていないことがわかる。また、
担子菌としてアガリクスタケ、マスタケ、ブナシメジを
用いて製造した清酒(実施例1品〜4品、7品、8品)
は、線溶活性を示していることも確認できる。さらに、
実施例1品〜9品の清酒は、市販の清酒(比較例品)に
比べ、抗トロンビン活性を示していることも確認でき
る。From the results shown in Tables 1 to 3, the sake produced by saccharification and alcohol fermentation of starch by basidiomycetes having amylase activity and alcohol dehydrogenase activity (Examples 1 to 8) had physiological activities. Β- which is a substance
It can be seen that D-glucan is contained. It is also found that the sake (Example 9 product ) produced by alcoholic fermentation with a basidiomycete having amylase activity and alcohol dehydrogenase activity also contains β-D-glucan. On the other hand, commercially available sake (comparative example) has β
It can be seen that -D-glucan is not included. Also,
Sake produced using Agaricus ttake mushrooms, mustard mushrooms and beech mushrooms as basidiomycetes (Examples 1 to 4, 7 and 8 products)
Can also be confirmed to exhibit fibrinolytic activity. further,
It can also be confirmed that the sakes of Examples 1 to 9 exhibit antithrombin activity as compared with commercially available sake (comparative example).
【0050】[0050]
【発明の効果】以上のように、本発明の清酒の製造は、
従来の清酒の製造における発酵工程、 あるいは、糖化工
程および発酵工程において、こうじ菌,酵母に代えて、
アミラーゼ活性およびアルコール脱水素酵素活性を有す
る担子菌を用い、この担子菌によってデンプンの糖化,
アルコール発酵を行うものである。そのため、酵母では
産出できない、抗ガン性物質(β−D−グルカン)等が
含有した全く新規の清酒が得られる。したがって、従来
には全くない、機能性・健康飲料を提供することができ
る。As described above, the production of sake according to the present invention is
Fermentation step in the production of conventional sake, or instead Oite, Koji fungus, a yeast as saccharification and fermentation engineering,
Basidiomycetes having amylase activity and alcohol dehydrogenase activity were used to saccharify starch,
Alcohol fermentation is performed. Therefore, completely new sake containing anti-cancer substance (β-D-glucan) and the like, which cannot be produced by yeast, can be obtained. Therefore, it is possible to provide a functional and healthy beverage that has never existed before.
【0051】そして、上記担子菌を用いれば、嫌気条件
下だけでなく、好気条件下でも清酒を製造することが可
能になるという利点がある。そのため、清酒の製造条件
の緩和が図れるという利点がある。嫌気条件下で特定の
担子菌によりアルコール発酵を行えば、従来の製造設備
をそのまま利用することができ、新規設備を増設等する
ことなく清酒の製造が行えるという利点がある。The use of the above basidiomycetes has an advantage that sake can be produced not only under anaerobic conditions but also under aerobic conditions. Therefore, there is an advantage that the production conditions of sake can be relaxed. If alcohol fermentation is carried out with a specific basidiomycete under anaerobic conditions, conventional manufacturing equipment can be used as it is, and there is an advantage that sake can be manufactured without adding new equipment.
【図1】本発明の清酒の製法の手順を示すフローシー
トである。FIG. 1 is a flow sheet showing a procedure of a method for producing sake according to the present invention.
【図2】本発明の清酒の製法の手順を示すフローシー
トである。FIG. 2 is a flow sheet showing a procedure of a method for producing sake according to the present invention.
【図3】実施例品の清酒のチャート図である。FIG. 3 is a chart of sake of example products .
【図4】比較例品の清酒のチャート図である。FIG. 4 is a chart of sake as a comparative example product.
【図5】従来の清酒の製法の手順を示すフローシートで
ある。FIG. 5 is a flow sheet showing a conventional procedure for producing sake .
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) C12G 1/00 - 3/14 C12C 1/00 - 13/10 JICST(JOIS) 食品関連文献情報(食ネット)─────────────────────────────────────────────────── ─── Continuation of the front page (58) Fields surveyed (Int.Cl. 7 , DB name) C12G 1/00-3/14 C12C 1/00-13/10 JISST (JOIS) Food-related literature information (food net) )
Claims (6)
アミラーゼ活性およびアルコール脱水素酵素活性を有す
る担子菌によってアルコール発酵を行うことを特徴とす
る清酒の製法。1. In the fermentation process in the production of sake,
A method for producing sake, which comprises carrying out alcohol fermentation with a basidiomycete having amylase activity and alcohol dehydrogenase activity.
工程において、アミラーゼ活性およびアルコール脱水素
酵素活性を有する担子菌によってデンプンの糖化とアル
コール発酵を行うことを特徴とする清酒の製法。2. A saccharification process and fermentation in the production of sake.
In the process , saccharification and algalization of starch by basidiomycetes having amylase activity and alcohol dehydrogenase activity are performed.
A method for producing sake characterized by performing coal fermentation .
水素酵素活性を有する担子菌が、アガリクスタケ、ヒラ
タケ、エノキタケ、マツタケ、キクラゲ、クリタケ、シ
イタケ、ショウロ、スエヒロタケ、タモギタケ、チョウ
レイマイタケ、ブクリョウ、ブナシメジ、マイタケ、マ
スタケ、マンネンタケ、ツクリタケ、ヤナギマツタケ、
ヤマブシタケ、カワラタケ、コフキサルノコシカケ、ナ
メコ、ヌメリスギタケ、アミガサタケ、キシメジ、シロ
ハツ、ツガサルノコシカケ、ノウタケ、ハエヤドリタ
ケ、ホウキタケ、マツタケモドキ、ムラサキシメジ、ヤ
マイグチ、クロハツ、ハタケシメジおよびヤマドリタケ
からなる群から選ばれた少なくとも一種である請求項1
または2記載の清酒の製法。3. A basidiomycete having an amylase activity and an alcohol dehydrogenase activity as described above ,
Bamboo, enokitake, matsutake, jellyfish, chestnut, shii
Bamboo shoots, gyoza, suehirotake, taro mushrooms, butterflies
Rei Maitake, Bukyou, Beech Shimeji, Maitake, Ma
Bamboo shoots, Ganoderma lucidum, Tsukuritake mushrooms, Salix matsutake mushrooms,
Yamabushitake, Kawaratake, Kobukisarunokeshi, Na
Meko, Numerisugitake, Morel mushroom, Kishimeji, White
Hearts, Tsugasaru-no-shikake, Noritake, Haeadorita
Bamboo, broom, matsutake mushroom, murasakishimeji, ya
Maiguchi, Kurohatsu, Hatake shimeji and Boletus edulis
2. At least one selected from the group consisting of
Alternatively, the method for producing sake described in 2 .
項1〜3のいずれか一項に記載の清酒の製法。4. The method for producing sake according to claim 1, wherein the alcoholic fermentation is performed under anaerobic conditions.
項1〜3のいずれか一項に記載の清酒の製法。5. The method for producing sake according to claim 1, wherein the alcoholic fermentation is carried out under aerobic conditions.
酒の製法により得られることを特徴とする清酒。6. Sake produced by the method for producing sake according to any one of claims 1 to 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000105456A JP3362313B2 (en) | 2000-04-06 | 2000-04-06 | Sake production method and the resulting sake |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000105456A JP3362313B2 (en) | 2000-04-06 | 2000-04-06 | Sake production method and the resulting sake |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001286275A JP2001286275A (en) | 2001-10-16 |
| JP3362313B2 true JP3362313B2 (en) | 2003-01-07 |
Family
ID=18618803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000105456A Expired - Fee Related JP3362313B2 (en) | 2000-04-06 | 2000-04-06 | Sake production method and the resulting sake |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3362313B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100750045B1 (en) * | 2005-08-19 | 2007-08-16 | 김일두 | Medicine, Takju manufacturing method using mushrooms |
| JP2012055307A (en) * | 2010-08-09 | 2012-03-22 | Tottori Univ | Development of system for efficient ethanol production from biomass using mushroom |
| JP5850636B2 (en) * | 2011-04-27 | 2016-02-03 | サッポロビール株式会社 | Method for alcoholic fermentation and / or culture of yeast |
-
2000
- 2000-04-06 JP JP2000105456A patent/JP3362313B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001286275A (en) | 2001-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Melanouri et al. | Cultivating Pleurotus ostreatus and Pleurotus eryngii mushroom strains on agro-industrial residues in solid-state fermentation. Part I: Screening for growth, endoglucanase, laccase and biomass production in the colonization phase | |
| CN102599481A (en) | Method for preparing solid fermentation mixed edible medicinal fungus sporocarp | |
| CN105231166A (en) | Active ferment with high SOD content and preparation method thereof | |
| Landingin et al. | Optimization of culture conditions for mycelial growth and basidiocarp production of Cyclocybe cylindracea (Maire) | |
| Elkhateeb et al. | Mushrooms as efficient enzymatic machinery | |
| CN104173389B (en) | A kind of Cordyceps militaris ferment powder and preparation method thereof | |
| CN103087893B (en) | Preparation method of composite coarse cereals monascus | |
| CN1339581A (en) | Large-scale deep liquid fermentation process for gray tree flower | |
| JP3362313B2 (en) | Sake production method and the resulting sake | |
| JP3362310B2 (en) | Method for producing alcoholic beverage and alcoholic beverage obtained thereby | |
| CN110923281B (en) | Edible fungus polysaccharide extraction method, edible fungus polysaccharide and edible fungus beverage | |
| CN102742690B (en) | Health-care functional tea and preparation method thereof | |
| CN103864504B (en) | Cultivate solid fermentation matrix of edible medicinal fungus and its production and use | |
| JP3362312B2 (en) | Beer production method and beer obtained thereby | |
| KR100874664B1 (en) | Method of making shiitake mushrooms | |
| JP3362311B2 (en) | Wine making method and wine obtained by it | |
| KR102580526B1 (en) | Method of Preparing Soybean Fermented Mycelium | |
| CN113912750A (en) | Method for extracting ganoderma lucidum fruiting body polysaccharide through fermentation pretreatment | |
| CN1052628C (en) | Edible fungus mycelium suspension beverage and production method thereof | |
| KR20040067175A (en) | Method for preparing immune enhancing polysaccharides | |
| KR20100115425A (en) | Functional drinks | |
| Kaur et al. | Production of oxidative and hydrolytic enzymes from Pleurotus florida and their implication in mushroom cultivation | |
| CN106520579B (en) | A kind of Serratieae fermentation liquid culture medium promoting the gill fungus growth and development of spot jade | |
| CN117551563A (en) | Composite fungus glycopeptide manufacturing process, liquid culture medium and preparation method of solid culture medium | |
| CN105441297B (en) | A kind of preparation method of kudzu root vinegar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081025 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091025 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101025 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111025 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111025 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121025 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |